arrow-right cart chevron-down chevron-left chevron-right chevron-up close menu minus play plus search share user email pinterest facebook instagram snapchat tumblr twitter vimeo youtube subscribe dogecoin dwolla forbrugsforeningen litecoin amazon_payments american_express bitcoin cirrus discover fancy interac jcb master paypal stripe visa diners_club dankort maestro trash




11 months ago

ワクチンとともに使用するCBDの生存可能性に関する新しい研究がありました。  オレゴン州立大学のヴァン·ブレーメン博士が研究結果を説明します。






彼は「伝染病の主な懸念の一つは変種の拡散であり、そのうちB.1.1.7B.1.351が最も広範囲で憂慮される」と付け加えた。「これらの変種は、初期系統のSARS-CoV-2に対する抗体を避けることで有名です。現在のワクチン接種戦略は、初期系統のスパイクタンパク質に抗原として依存していることを考えると、明らかに懸念されています。 私たちのデータによると、CBDACBGAは、私たちが検討した2つのバリアントに対して効果的であることが示されています。この傾向が、他の既存および将来のバリアントにも拡大することを期待しています。」



There has been new research into the viability of CBD for use in conjunction with vaccines.  Dr. Van Breemen from the Oregon State University explains his findings.



According to Van Breemen, “Cannabinoids can be taken orally and have a long history of safe use in humans,”.  “They have the potential to prevent as well as treat infection by SARS-CoV-2.  CBDA and CBGA are produced by the hemp plant as precursors to CBD and CBG, which are familiar to many consumers. However, they are different from the acids and are not contained in hemp products.”



Van Breemen explains that affinity selection mass spectrometery, which he abbreviates to AS-MS, involves incubating a drug target like the SARS-CoV-2 spike protein with a mixture of possible ligands – things that might bind to it – such as a botanical extract, in this case hemp extract.



The ligand-receptor complexes are then filtered from the non-binding molecules using one of several methods.



“We identified several cannabinoid ligands and ranked them by affinity to the spike protein,” van Breemen said. “The two cannabinoids with the highest affinities for the spike protein were CBDA and CGBA, and they were confirmed to block infection.



“One of the primary concerns in the pandemic is the spread of variants, of which there are many, and B.1.1.7 and B.1.351 are among the most widespread and concerning,” he added. “These variants are well known for evading antibodies against early lineage SARS-CoV-2, which is obviously concerning given that current vaccination strategies rely on the early lineage spike protein as an antigen. Our data show CBDA and CBGA are effective against the two variants we looked at, and we hope that trend will extend to other existing and future variants.”



Van Breemen said resistant variants could still arise amid widespread use of cannabinoids but that the combination of vaccination and CBDA/CBGA treatment should make for a much more challenging environment for SARS-CoV-2.